Insider Purchases: Inside the Buy
Tag: Stock Analysis 2026
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
TTD Stock Analysis 2026: Jeff Green’s $148M Bet — Is The Trade Desk the Ultimate “Buy the Dip” Play?
The Trade Desk just got the loudest kind of bullish signal: the founder-CEO bought $148M of his own stock after an 80%+ drawdown. Institutions are stacked, shorts are circling, and valuation has finally cooled from “bubble” to “business.” The question now: is TTD a generational dip… or a beautiful trap?
NOW Stock Analysis 2026: Bill McDermott’s $3M “Strong Buy” Signal — Is ServiceNow the AI Control Tower?
ServiceNow (NOW) is fighting a valuation reset with AI-powered fundamentals. CEO Bill McDermott just made a rare $3M insider buy — a signal worth decoding.
FOUR Stock Analysis 2026: Is Shift4 a Payments Powerhouse or a Falling Knife?
Shift4 (FOUR) is a full-blown battleground stock. Founder buying, 35% short interest, heavy institutional ownership, and a forward P/E near 7. Rocket fuel — or engine trouble?
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.
